{'fraction_non_alphanumeric': 0.015463917525773196, 'fraction_numerical': 0.0010309278350515464, 'mean_word_length': 5.516778523489933, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Angiotensin Receptor Blockers

It is well recognised that the angiotensin receptor blockers (ARBs) are the drugs of choice when starting therapy in patients with type 2 diabetes mellitus presenting with renal damage. It is also widely recognised that as soon as minor abnormalities of renal function are present, in either diabetic or non-diabetic patients, the cardiovascular risk is significantly increased. As a consequence, the renal protection offered by an ARB through the blockade of angiotensin II and its effects must be accompanied by simultaneous cardiovascular protection in a magnitude similar to that offered by an angiotensin converting enzyme (ACE) inhibitor.Recent data obtained in studies of patients with hypertension, heart failure, and myocardial infarctions, confirm that the specific indication for the use of ARBs in renal protection is accompanied by a degree of cardiovascular protection at least similar to that demonstrated by ACE inhibitors.